Androgen-deprivation therapy is associated with Alzheimer's disease
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Androgen-deprivation therapy (ADT) in patients with prostate cancer is associated with the development of Alzheimer's disease.
Why this matters
Clinicians considering treating prostate cancer with ADT may also want to consider the patient's risk for Alzheimer's disease as well.
Patients were divided into 4 groups: non-ADT (patients who never received ADT; n=8401), patients who received injections for at least 3 mo (injection cohort [INJ]; n=1008), patients who received oral therapy for at least 3 mo (n=9963), and patients who received injections and oral medication (n=4905).
Non-ADT incidence of AD was 2.78/1000 person-years and 5.66/1000 in the ADT cohort.